CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 130 filers reported holding CYMABAY THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 2.94 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $384,000 | -4.0% | 88,102 | 0.0% | 0.01% | -14.3% |
| Q1 2021 | $400,000 | -20.9% | 88,102 | 0.0% | 0.01% | -22.2% |
| Q4 2020 | $506,000 | -20.7% | 88,102 | 0.0% | 0.02% | -25.0% |
| Q3 2020 | $638,000 | +107.8% | 88,102 | 0.0% | 0.02% | +100.0% |
| Q2 2020 | $307,000 | +136.2% | 88,102 | 0.0% | 0.01% | +100.0% |
| Q1 2020 | $130,000 | -24.9% | 88,102 | 0.0% | 0.01% | -14.3% |
| Q4 2019 | $173,000 | -61.6% | 88,102 | 0.0% | 0.01% | -65.0% |
| Q3 2019 | $451,000 | -28.5% | 88,102 | 0.0% | 0.02% | -23.1% |
| Q2 2019 | $631,000 | -66.5% | 88,102 | -48.2% | 0.03% | -61.8% |
| Q3 2018 | $1,883,000 | -17.4% | 169,962 | 0.0% | 0.07% | -21.8% |
| Q2 2018 | $2,281,000 | +3.3% | 169,962 | 0.0% | 0.09% | +1.2% |
| Q1 2018 | $2,208,000 | +14.3% | 169,962 | -19.1% | 0.09% | +14.7% |
| Q4 2017 | $1,932,000 | +14.2% | 209,962 | 0.0% | 0.08% | +25.0% |
| Q3 2017 | $1,692,000 | – | 209,962 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |